MARKET OUTLOOK Atherosclerotic cardiovascular disease (ASCVD) broadly covers coronary artery disease, including acute coronary syndrome, a history of myocardial infarction, stable or unstable…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
MARKET OUTLOOK First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a…
Treatment of heart failure with reduced ejection fraction (HFrEF) is well established with a wealth of evidence from clinical trials that supports the use of all standard-of-care therapies for CHF…
Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates…
Clarivate Epidemiology's coverage of coronary heart disease (CHD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology's coverage of coronary heart disease (CHD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology's coverage of coronary heart disease (CHD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology's coverage of coronary heart disease (CHD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
Clarivate Epidemiology's coverage of coronary heart disease (CHD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Coronary Heart Disease patient populations covering 171 countries…
Heart failure is a major public health burden in China. With a rapidly rising urban population and a growing trend in unhealthy lifestyles, heart failure is expected to affect a sizable population…
Nocturnal polyuria, a key contributing factor of nocturia in adults, is characterized by overproduction of urine at night. Changes in lifestyle and circadian rhythms, and conditions such as…
DRG Epidemiology's coverage of heart failure (HF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed event rates of AHF…
